Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia

Secondary acute myeloid leukemia (sAML) is a high-risk AML evolving from heterogenous prior hematological disorders. Compared to de novo AML, sAML has even worse responses to current therapy and thus is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. M...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hui Zhang, Wen-Ting Gan, Wen-Ge Hao, Peng-Fei Wang, Zhuo-Yan Li, Lung-Ji Chang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2020-05-01
coleção:	Frontiers in Oncology
Assuntos:	secondary acute myeloid leukemia myelodysplastic syndrome myeloproliferative neoplasm CAR T-cell therapy CLL1
Acesso em linha:	https://www.frontiersin.org/article/10.3389/fonc.2020.00685/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!